The Medicines Co.

The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity

Pair of Arch, Ra portfolio companies file to list on NASDAQ

Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s

Deal for up to $1.1B with ‘significant upfront payment’ rewards syndicate including Westlake and Versant, gives pharma three preclinical programs for muscular dystrophies

In BioCentury’s latest Clinical Report, Wave gains on DMD data, plus updates from Daiichi and AZ, Black Diamond, Metsera, Biohaven and more

Plus fundings for Asher, Pathios, Outrun and Theolytics

Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more

Plus: Vertex’s diabetes cell therapy leads to insulin independence; Agios heads to Phase III in sickle cell; and updates from Biomea, Shionogi, Sagimet and more

Can the Swiss pharma crack into the top five in the U.S. market, based on its current pipeline?

Start-up co-founded by Population Health Partners and backed by Bain has Phase III-ready oral candidate that could compete with biologics